HBMN.SW HBM Healthcare (SIX) CHF237 intraday 19 Jan 2026: earnings due 23 Jan could shift valuation
HBMN.SW stock trades at CHF237.00 intraday on 19 Jan 2026, down -0.84% for the day. The fund reports results on 23 Jan 2026, a near-term catalyst that could move the share price. We review valuation, portfolio exposure, technicals and model forecasts to frame trading scenarios ahead of the earnings release.
Earnings calendar and catalysts for HBMN.SW stock
HBM Healthcare Investments AG (HBMN.SW) will publish its earnings on 23 Jan 2026. The report can change the market view of net asset value, realised gains and dividend capacity. Expect commentary on follow-on investments and exits from late-stage private equity and biotech holdings. Watch the NAV disclosure and any update on dividend policy, since the company paid CHF7.50 per share last year.
Quarterly metrics and valuation for HBMN.SW stock
HBMN.SW shows a trailing EPS of 13.66 and a PE of 17.31. Book value per share stands at CHF251.31, giving a price-to-book of 0.94. The stock yields around 3.17% based on dividend metrics. Compared with the Financial Services sector average PE of 16.81, HBMN.SW trades slightly richer on earnings but cheaper on book value. Investors should weigh the fund’s private asset mix against these ratios.
Portfolio exposure and sector context for HBMN.SW stock
HBM Healthcare invests mostly in later-stage private and public healthcare companies. The portfolio focuses on pharma, biotech, diagnostics and medtech, giving investors indirect exposure to the Healthcare sector. This creates a hybrid profile: equity fund metrics but sensitivity to clinical news and sector moves. The Swiss Healthcare sector has gained 8.07% over one month, which can buoy NAVs if portfolio valuations rerate.
Technical picture and Meyka AI grade for HBMN.SW stock
The intraday technicals show momentum but limited volume. RSI sits at 67.73, ADX at 34.98 indicating a strong trend, and the 50-day average is CHF215.58 versus the current price CHF237.00. Average daily volume is 8,771, while today’s volume is 604, signalling light trading ahead of earnings.
Meyka AI rates HBMN.SW with a score out of 100: 69.97 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not financial advice.
Meyka AI forecast and scenario targets for HBMN.SW stock
Meyka AI’s forecast model projects monthly CHF238.04, quarterly CHF181.09 and yearly CHF109.01. The monthly forecast implies an upside of 0.44% versus the current CHF237.00. The quarterly and yearly projections imply downside of -23.60% and -54.00% respectively. Forecasts are model-based projections and not guarantees. Scenario price targets: conservative CHF260.00 (upside 9.70%), base CHF300.00 (upside 26.58%), and downside CHF180.00 (downside -24.05%) depending on NAV and exit outcomes.
Earnings risk and what to watch on 23 Jan 2026 for HBMN.SW stock
Key risks ahead of earnings include weak realised gains from exits, NAV markdowns from clinical failures, and lower distributable income. Liquidity is another factor: the fund’s average volume is 8,771, so big trades can swing price. Analysts classify company ratings as B+ / Neutral, so guidance or unexpected write-downs could prompt a re-rating. For background see the Bloomberg company profile and PEX holdings where HBMN’s strategy and holdings are discussed Bloomberg ProShares PEX holdings.
Final Thoughts
HBMN.SW stock trades at CHF237.00 intraday on 19 Jan 2026 with earnings due on 23 Jan 2026 as the main short-term catalyst. Valuation shows a PE of 17.31, book value per share CHF251.31, and a dividend history supporting a 3.17% yield. Technicals indicate momentum but low liquidity today, so price swings are likely around the report. Meyka AI’s model projects a near-term monthly value of CHF238.04, implying a small upside of 0.44%, while longer-dated scenarios show larger downside if NAVs reset. Investors should watch NAV disclosures, realised exit gains, and dividend commentary. Our scenarios provide a framework: conservative upside to CHF260.00, base around CHF300.00, and downside near CHF180.00. Use these figures to frame risk management before the earnings release. Meyka AI is an AI-powered market analysis platform offering model-based forecasts; forecasts are projections and not guarantees.
FAQs
When does HBM Healthcare report earnings and why does it matter for HBMN.SW stock?
HBM Healthcare reports on 23 Jan 2026. The earnings release can change NAV, reveal realised gains or losses, and affect dividend expectations. For HBMN.SW stock this report is the main near-term price catalyst.
What valuation metrics should investors check for HBMN.SW stock?
Focus on PE (17.31), book value per share CHF251.31, and dividend yield 3.17%. Also compare price-to-book versus peers and monitor NAV changes for HBMN.SW stock.
How does Meyka AI view HBMN.SW stock ahead of earnings?
Meyka AI rates HBMN.SW 69.97 (Grade B, HOLD) and models a near-term monthly target of CHF238.04. This outlook is model-based and not a guaranteed outcome for HBMN.SW stock.
What are realistic trading scenarios for HBMN.SW stock after earnings?
Bull case supports CHF260.00 to CHF300.00, base case holds near current price, and downside could reach CHF180.00 if NAVs are marked down. These scenarios help size risk for HBMN.SW stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
